Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

New Haven, Connecticut's Hospital of Saint Raphael has decided to suspend use of 197 of the 250 generic products used at the hospital due to "concern for patient safety." The hospital announced Oct. 16 that its Pharmacy and Therapeutics Committee had "recommended the replacement of 80% of the generic drugs now being used at the 491-bed community teaching hospital with brand-name equivalents." The hospital said that the action is "effective immediately" and will cost "an estimated $100,000 a year." St. Raphael maintained that the additional expense "is not expected to affect patients." The hospital is the sixth largest in the state. St. Raphael cited the "alleged unethical conduct by some generic drug companies" in explaining the committee's decision. However, the hospital said it will continue to use generic drugs supplied by Elkins-Sinn, LyphoMed and Roxane Labs. The hospital said it will continue to dispense generic drugs from the three manufacturers "because hospital officials have no reason to suspect unethical conduct on the part of" these companies. The three generic firms supply "about 50 drugs" used by St. Raphael Hospital. The hospital said its pharmacy fills 2.5 mil. doses a year from its stock of roughly 1,000 drugs. Until now, generics have represented "about half" the medications dispensed. The Generic Pharmaceutical Industry Association said that St. Raphael is the first hospital it is aware of that has taken such a step in response to the ongoing generic scandal.

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts